mucositis


Also found in: Wikipedia.

mucositis

 [mu″ko-si´tis]
inflammation of a mucous membrane.

mucositis

(myū-kō-sī'tis),
Inflammation of a mucous membrane.
[mucosa + -itis]

mucositis

[myo̅o̅′kōsī′tis]
any inflammation of a mucous membrane, such as the lining of the mouth and throat.

mucositis

Inflammation of a mucosa which, in the GI tract, appears as oral ulcers. See Stomatitis.

mu·co·si·tis

(myūkō-sītis)
Inflammation of a mucous membrane
[mucosa + -itis]

mucositis (mū´kōsī´tis),

n an inflammation of the mucous membrane.
mucositis, chronic atrophic senile,
n oral mucosal inflammation characterized by atrophy and found primarily in elderly women.
mucositis, fusospirochetal,
n oral mucosal inflammation associated with fusiform and spirochetal microorganisms.

mucositis

inflammation of a mucous membrane.
References in periodicals archive ?
5m SBIR Grant for Clinical Trial of SGX942 for Treatment of Oral Mucositis
United States-based Oragenics has dosed the first patient in its phase two clinical trial of AG013 intended for the treatment of oral mucositis, it was reported yesterday.
Mucositis is a common and frequently severe complication associated with the damaging effects of radiation on healthy mucosal tissue, usually occurring 2-3 weeks after commencement of radiotherapy.
The incidence of moderate-to-severe oral mucositis was significantly lower in the active-treatment group than in the control group (20% vs.
The firm said the mouthwash has been developed to prevent oral mucositis, one of the most common and debilitating complications of chemotherapy and radiation.
Global Markets Direct's, 'Oral Mucositis - Pipeline Review, H2 2015', provides an overview of the Oral Mucositis's therapeutic pipeline.
PARK CITY, UTAH -- According to emerging evidence in the medical literature, Mycoplasma pneumoniae-induced rash and mucositis is a distinct clinical entity with a distinct etiology and a good prognosis.
However, while in vivo animal models of chemotherapy and radiotherapy-induced oral mucositis have been successfully established, alternative methods such as in vitro tools for mucositis are still missing.
was given an SBIR award to fund the development of genetically-modified mesenchymal stem cells treated with Targazyme's lead product, TZ101 for treatment of oral mucositis.
Background: Anemia and oral mucositis are main side effects of radiotherapy (RT) and are important factors affecting the quality of life (QOL) in head and neck cancer (HNC) patients treated with RT.
An evidence-based protocol for dental care with specific treatment modalities, including the prevention and treatment of oral mucositis (OM), is included.
This initial target indication is pain management for patients suffering from oral mucositis during cancer therapy.